Journal
VACCINE
Volume 35, Issue 29, Pages 3615-3620Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2017.05.022
Keywords
Parvovirus B19 vaccine; Yeast-derived; Intramuscular; Sickle cell disease; Systemic antibody; Mucosal antibody response
Categories
Funding
- Children's Infection Defense Center at St. Jude
- NIH NCI [P30 CA21765]
- Intramural Research Program of the NIH, NHLBI
- ALSAC
Ask authors/readers for more resources
Parvovirus B19 infections are typically mild in healthy individuals, but can be life threatening in individuals with sickle cell disease (SCD). A Saccharomyces cerevisiae-derived B19 VLP vaccine, now in pre-clinical development, is immunogenic in wild type mice when administered with the adjuvant MF59. Because SCD alters the immune response, we evaluated the efficacy of this vaccine in a mouse model for SCD. Vaccinated mice with SCD demonstrated similar binding and neutralizing antibody responses to those of heterozygous littermate controls following a prime-boost-boost regimen. Due to the lack of a mouse parvovirus B19 challenge model, we employed a natural mouse pathogen, Sendai virus, to evaluate SCD respiratory tract responses to infection. Normal mucosal and systemic antibody responses were observed in these mice. Results demonstrate that mice with SCD can respond to a VLP vaccine and to a respiratory virus challenge, encouraging rapid development of the B19 vaccine for patients with SCD. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available